A novel Composite Endpoint of Liver Surgery (CELS) has been developed to enhance the feasibility of clinical trials in liver surgery by significantly reducing required sample sizes. Analyzing data from 1,958 patients, researchers found that 19.3% met CELS criteria, demonstrating strong predictive accuracy for surgery-related death with area under the curve values of 0.79 and 0.85 in analytic and validation cohorts respectively. CELS allows for a 45.8-91.6% reduction in sample size compared to single endpoints.
Journal Article by Kawashima J, Akabane M (…) Pawlik TM et 25 al. in Ann Surg Oncol
© 2025. The Author(s).